Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617074 | 0.91 | TLR7 (0.45) | TLR7 | |
| SCHEMBL16624357 | 0.89 | DHFR (0.33) | TLR7MEN1LMNAMAPTKMT2A | |
| SCHEMBL16624359 | 0.87 | DHFR (0.34) | TLR7MEN1LMNAMAPTKMT2A | |
| SCHEMBL15305573 | 0.82 | MEN1 (0.34) | MEN1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL16616829 | 0.81 | TLR7 (0.39) | TLR7 | |
| SCHEMBL16624353 | 0.79 | TLR7 (0.44) | TLR7 | |
| SCHEMBL4203291 | 0.79 | TLR7 (0.39) | TLR7MEN1LMNAMAPTKMT2A | |
| SCHEMBL853422 | 0.79 | TLR7 (0.38) | TLR7DHFR | |
| SCHEMBL16624354 | 0.78 | TLR7 (0.41) | TLR7MAPTKMT2ASMN1; SMN2DHFR | |
| SCHEMBL6123086 | 0.77 | TLR7 (0.45) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9376398-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | C9, SUCNR1, C3AR1 | TLR7 87/4885MEN1 95/4885LMNA 2618/4885 |
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | C9, SUCNR1, C3AR1 | TLR7 87/4885MEN1 95/4885LMNA 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.